{"entity":{"id":"biocad","kind":"company","name":"Biocad","aka":["BIOCAD"],"tldr":"Biocad is a Russian biotechnology company that makes biosimilars of rituximab, bevacizumab and trastuzumab and developed prolgolimab, the first anti-PD-1 antibody approved in Russia, now tested with its anti-CTLA-4 partner nurulimab in melanoma.","summary":"Biocad, based in St Petersburg, is Russia's largest biotechnology company by its own account, with biosimilars of rituximab, bevacizumab and trastuzumab that supply much of the Russian market and an in-house immuno-oncology pipeline. Its anti-PD-1 antibody prolgolimab (BCD-100, brand name Forteca) received Russian approval for melanoma in 2020 and is in phase 3 trials as a fixed combination with the anti-CTLA-4 antibody nurulimab (BCD-217) in unresectable and resectable melanoma. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://biocad.ru/"},{"label":"ClinicalTrials.gov: trials led by Biocad","url":"https://clinicaltrials.gov/search?lead=Biocad"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["bcd-100","bcd-217"],"companies":[],"institutions":["blokhin-cancer-center","petrov-institute"],"pathways":[],"terms":[],"trials":["nct05732805","nct05751928","nct06640530","nct05802225","nct07108309","nct06668792","nct07742215"],"people":[],"bottlenecks":[],"keyPapers":["paper-tjulandin-prolgolimab-miraculum-ejc-2021","paper-laktionov-prolgolimab-domajor-ejc-2025"],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"St Petersburg","country":"RU","companyType":"biotech","website":"https://biocad.ru/","stage":"private-large","investors":[],"funding":[]},"route":"/companies/biocad/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"bcd-100","kind":"drug","name":"BCD-100","route":"/drugs/bcd-100/"},{"id":"bcd-217","kind":"drug","name":"BCD-217","route":"/drugs/bcd-217/"}],"institution":[{"id":"blokhin-cancer-center","kind":"institution","name":"N. N. Blokhin National Medical Research Center of Oncology","route":"/institutions/blokhin-cancer-center/"},{"id":"petrov-institute","kind":"institution","name":"N. N. Petrov National Medical Research Centre of Oncology","route":"/institutions/petrov-institute/"}],"trial":[{"id":"nct05732805","kind":"trial","name":"A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma","route":"/trials/nct05732805/"},{"id":"nct05751928","kind":"trial","name":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","route":"/trials/nct05751928/"},{"id":"nct07742215","kind":"trial","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","route":"/trials/nct07742215/"},{"id":"nct06668792","kind":"trial","name":"An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06668792/"},{"id":"nct07108309","kind":"trial","name":"BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer","route":"/trials/nct07108309/"},{"id":"nct05802225","kind":"trial","name":"Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer","route":"/trials/nct05802225/"},{"id":"nct06640530","kind":"trial","name":"Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin","route":"/trials/nct06640530/"}],"paper":[{"id":"paper-laktionov-prolgolimab-domajor-ejc-2025","kind":"paper","name":"DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer","route":"/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/"},{"id":"paper-tjulandin-prolgolimab-miraculum-ejc-2021","kind":"paper","name":"MIRACULUM: prolgolimab, the first Russian-developed anti-PD-1 antibody, in advanced melanoma","route":"/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/"}]}}